Literature DB >> 11975819

Intraoral chilling versus oral sumatriptan for acute migraine.

M H Friedman1, S J Peterson, C F Behar, Z Zaidi.   

Abstract

Migraine pathophysiology is associated with a dural inflammation. Recent evidence suggests that the primary inflammation occurs in a maxillary nerve segment, accessible intraorally. Local tenderness, related to symptom laterality, has been palpated consistently in asymptomatic migraine patients, and significant migraine relief has been obtained from chilling confined to this area. Thirty-five symptomatic episodic migraine patients were enrolled in this study, comparing 40 minutes of bilateral intraoral chilling, 50 mg of oral sumatriptan, and 40 minutes of sham (tongue) chilling. Hollow metal tubes chilled by circulating ice water were held in the maxillary molar periapical areas by the patient. Pain and nausea were recorded at baseline and 1, 2, 4, and 24 hours after start of treatment, using a numeric symptom-relief scale. Significant mean headache relief was obtained by maxillary chilling and sumatriptan at all four time intervals, with poor relief obtained by placebo. Maxillary chilling was more effective than sumatriptan at all four time intervals. Significant nausea relief was obtained by maxillary chilling and sumatriptan at posttreatment and 2 and 4 hours later. At 24 hours, some headache and nausea recurrence was noted with sumatriptan. The repeated-measures analysis of variance indicated that both treatments, drug (P = 0.024) and maxillary chilling (P = 0.001), reduced the headache, as compared with the control group. Tenderness suggests local inflammation associated with vasodilatation and edema. Because chilling can resolve local edema, these findings raise the possibility that an intraoral inflammation may be a factor in migraine etiology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11975819     DOI: 10.1097/00132580-200111000-00003

Source DB:  PubMed          Journal:  Heart Dis        ISSN: 1521-737X


  4 in total

1.  Randomized controlled trial: targeted neck cooling in the treatment of the migraine patient.

Authors:  Adam S Sprouse-Blum; Alexandra K Gabriel; Jon P Brown; Melvin Hc Yee
Journal:  Hawaii J Med Public Health       Date:  2013-07

2.  Cold Therapy in Migraine Patients: Open-label, Non-controlled, Pilot Study.

Authors:  Serap Ucler; Ozlem Coskun; Levent E Inan; Yonca Kanatli
Journal:  Evid Based Complement Alternat Med       Date:  2006-06-15       Impact factor: 2.629

3.  Therapeutic effect of intranasal evaporative cooling in patients with migraine: a pilot study.

Authors:  Jitka Vanderpol; Barbara Bishop; Manjit Matharu; Mark Glencorse
Journal:  J Headache Pain       Date:  2015-01-26       Impact factor: 7.277

4.  Acute migraine: Current treatment and emerging therapies.

Authors:  Arun A Kalra; Debra Elliott
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.